Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing giredestrant plus everolimus to physician's choice endocrine therapy plus everolimus in estrogen receptor–positive, HER2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Giredestrant (giredestrant)

Snippet

Sponsor: Genentech, Inc. | Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING